Thursday, 6 December 2018

Alemtuzumab as a cause of stroke

How does alemtuzumab cause stroke? It is unlikely to be due to secondary autoimmune disease as it occurs too soon after administration. Could it be due to a mechanism that triggers thrombotic mechanisms, for example via platelet activation? Alemtuzumab causes an early and transient low platelet count (thrombocytopenia), which may be related to thrombosis. 


Adapted excerpt from the FDA website:

The U.S. Food and Drug Administration (FDA) is warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) shortly after they received alemtuzumab. These problems can lead to permanent disability and even death. As a result, the FDA has added a new warning about these risks to the prescribing information in the drug label and to the patient Medication Guide. They have also added the risk of stroke to the existing Boxed Warning, FDA’s most prominent warning.

The FDA is recommending that patients or their caregivers should seek emergency treatment as soon as possible if the patient experiences signs or symptoms of a stroke or tears in the lining of the head and neck arteries, called arterial dissection, which can include:
  1. Sudden numbness or weakness in the face, arms, or legs, especially if it occurs on only one side of the body
  2. Sudden confusion, trouble speaking, or difficulty understanding speech
  3. Sudden trouble seeing in one or both eyes
  4. Sudden trouble with walking, dizziness, or loss of balance or coordination
  5. Sudden severe headache or neck pain
Most patients taking alemtuzumab who developed stroke or tears in the artery linings developed symptoms within 1 day of receiving alemtuzumab. One patient reported symptoms that occurred 3 days after treatment.

Health care professionals should advise patients at every alemtuzumab infusion to seek immediate emergency medical attention if they experience symptoms of ischemic or hemorrhagic stroke or cervicocephalic arterial dissection. The diagnosis is often complicated because early symptoms such as a headache and neck pain are not specific. Promptly evaluate patients who complain of symptoms consistent with these conditions.

In the nearly 5 years since FDA approved alemtuzumab in 2014 to treat relapsing forms of MS, the FDA have identified 13 worldwide cases of ischemic and hemorrhagic stroke or arterial dissection that occurred shortly after the patient received alemtuzumab (see Data Summary). This number includes only reports submitted to FDA,* so additional cases that they are unaware of may have occurred. Twelve of these cases reported symptoms within 1 day of receiving alemtuzumab. As a result, the FDA has added a new warning about this risk in the Warnings and Precautions section of the prescribing information in the drug label. They have also added the risk of stroke to the existing Boxed Warning, FDA’s most prominent warning.

To help FDA track safety issues with medicines, they are urging health care professionals to report side effects from Alemtuzumab or other medicines to the FDA MedWatch program.

CoI: multiple

11 comments:

  1. I've mentioned today under MD's Fingolimod and warts post that on his YouTube vids Aaron Boster produced one a couple of days ago. He's making a correlation between blood pressure and the risk of stroke and arterial dissection.

    ReplyDelete
    Replies
    1. I wonder what a cytokine storm from the bursting of cells does to blood pressure

      Delete
  2. It seems there are more problems than benefits with this drug! I'm so glad I chose Natalizumab over this when I was given the option at diagnoses.

    ReplyDelete
    Replies
    1. As someone who chose to receive Alemtuzumab I can't agree Anon.
      I think that those of us with RRMS, with access to DMTs, are fortunate to have options.
      I'm glad Nat is working for you and pleased Alem is working for me.
      Reckon our hopes should now be for available treatments for SPMS and PPMS.

      Delete
    2. same here - but the sad truth is that we will both progress to SPMS with campath may offer a cure.

      Delete
  3. Why don't more folk opt for Cladribine?

    ReplyDelete
    Replies
    1. It has only just become available and carries baggage
      Some neuros are frightened of itbut once they use they can see it can be a give and forget drug.
      We have over250 people taking this, . To put in perspective Cambridge have less than 200 people who have taken CAMPATH,so for us this comment os os not.relevant

      Delete
  4. Alem. has these serious side effects (and no attempt to at least eliminate the secondary autoimmunity issues), Cladribine does not have a satisfying effect on brain atrophy rates -antiCD20s and Tysabri neither do- and HSCT is harsh and not available to most patients.

    If you were dreaming of a reasonably easy way out from MS, well the news are not great...

    ReplyDelete
  5. As i keep saying the trials cant be directly compared. You save nrain if you get on a highly active.treatmemt early.

    ReplyDelete
  6. I really want to save brain, but things are starting to sound ridiculous in terms of side effects. Having options is great, but none sound right. Thanks for all you do for us!! Please continue the fantastic work.

    ReplyDelete
  7. Alemtuzumab is still the most interesting drug for MS, even as an add-on.

    Alemtuzumab-containing reduced intensity conditioning allogenic hematopoietic stem cell transplantation in a case of primary progressive multiple sclerosis.
    "His second HSCT was conditioned with an alemtuzumab containing regimen, after which his MRI and expanded disability status scale (EDSS) remained to be stable for 18 months."
    https://www.ncbi.nlm.nih.gov/pubmed/30195202?dopt=Abstract&fbclid=IwAR0ZH-xhrcrOwpEAcnrJSq58m5W1xT0ezMHXqtLl717J7bFgO8fRH0fAph0

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.